Monica Soni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Monica Soni has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Arti Meena
Department of Obstetrics and Gynecology, SPMC, Bikaner, Rajasthan, India
1 shared publication- Arvind Pareek
Department of Botany, Maharshi Dayanand Saraswati University, Ajmer, India
1 shared publication - Ashok Muniappan
Thoracic Surgery, Massachusetts General Hospital, Boston, MA, United States
1 shared publication Brandon Ferrell
Georgetown University
1 shared publicationCameron D. Wright
Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Massachusetts
1 shared publicationColin Wikholm
Georgetown University
1 shared publication
Latest Publications
- 1 February 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 113 (2) , 406-412
Evaluation of Release Maneuvers After Airway Reconstruction
- 1 February 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 113 (2) , 406-412
Evaluation of Release Maneuvers After Airway Reconstruction
- Open Access
- 26 August 2021
- Published by Medip Academy in International Journal of Reproduction, Contraception, Obstetrics and Gynecology
- Vol. 10 (9) , 3486-3489
Study of effect of intra-umbilical oxytocin along with active management in third stage of labor
Background: The aim of the study was to determine effect of intra-umbilical oxytocin along with active management on duration and amount of blood loss in 3rd of stage of labor. Methods: This was a hospital based prospective, randomized, case-control study conducted in the department of OBG between 1st September 2019 to 31st December 2020. After obtaining permission from ethical committee, screening of inclusion and exclusion criteria and informed consent of participants, 300 cases were enrolled. In group A (control) 20 ml normal saline and in group B (case) 20 IU oxytocin diluted in normal saline to make a 20 ml solution was given intra-umbilically along with standard active management of third stage labor. The data was systematically recorded and analysed. Results: Both the groups were comparable in terms of demographic data. A statistically significant reduction in the duration of third stage of labor (1.83±0.64 min in group B vs 2.92±0.79 min in group A), amount of blood loss (203.73±62.11 ml in group B vs 328.83±87.18 ml group A) and fall in haemoglobin (9.28±1.03 g/dl in the study group A vs 9.97±1.28 g/dl in group B) and haematocrit (31.20±3.05% in study group A vs 33.60±3.31% in study group B) were noted, taking p value significant Conclusions: Intra-umbilical oxytocin was associated with a significant reduction in duration and amount blood loss in third stage of labor.
- 26 August 2021
- Published by Medip Academy in International Journal of Reproduction, Contraception, Obstetrics and Gynecology
- Vol. 10 (9) , 3486-3489
Open AccessStudy of effect of intra-umbilical oxytocin along with active management in third stage of labor
Background: The aim of the study was to determine effect of intra-umbilical oxytocin along with active management on duration and amount of blood loss in 3rd of stage of labor. Methods: This was a hospital based prospective, randomized, case-control study conducted in the department of OBG between 1st September 2019 to 31st December 2020. After obtaining permission from ethical committee, screening of inclusion and exclusion criteria and informed consent of participants, 300 cases were enrolled. In group A (control) 20 ml normal saline and in group B (case) 20 IU oxytocin diluted in normal saline to make a 20 ml solution was given intra-umbilically along with standard active management of third stage labor. The data was systematically recorded and analysed. Results: Both the groups were comparable in terms of demographic data. A statistically significant reduction in the duration of third stage of labor (1.83±0.64 min in group B vs 2.92±0.79 min in group A), amount of blood loss (203.73±62.11 ml in group B vs 328.83±87.18 ml group A) and fall in haemoglobin (9.28±1.03 g/dl in the study group A vs 9.97±1.28 g/dl in group B) and haematocrit (31.20±3.05% in study group A vs 33.60±3.31% in study group B) were noted, taking p value significant Conclusions: Intra-umbilical oxytocin was associated with a significant reduction in duration and amount blood loss in third stage of labor.
- Open Access
- 27 May 2020
- Published by Medip Academy in International Journal of Reproduction, Contraception, Obstetrics and Gynecology
- Vol. 9 (6) , 2512-2515
Lomiphene citrate versus letrozole as first line ovulation induction drug in infertile anovulatory polycystic ovarian syndrome women: a prospective randomized controlled trial
Background: The present study was design to compare letrozole (5 mg) and clomiphene citrate (100 mg) as first line ovulation induction drug in infertile anovulatory polycystic ovarian syndrome (PCOS) women.Methods: This prospective randomized clinical trial included 60 cases of PCOS with anovulatory infertility. The first group comprised of 30 patients who received 5 mg letrozole daily and the second group received 100 mg clomiphene citrate daily for 5 days starting on day 2-5 of menses. Both the groups were followed by ultrasound for follicle monitoring, ovulation and endometrial thickness. When dominant follicle reaches a diameter of more than or equal to 18mm and endometrial thickness ≥7.5 mm, human chorionic gonadotrophin (hCG) 5,000 IU was given intramuscularly and timed intercourse was advised. Main outcome measures were occurrence of ovulation, endometrial thickness and pregnancy rates.Results: The mean age, body mass index, and number of cases of primary and secondary infertility in both the groups showed no statistically significant difference. Multi-follicular development during induction was statistically significantly greater in the clomiphene group (1.27±1.11 versus 2.03±1.65; p=0.041). Ovulation occurred in 24 subjects (80%) in letrozole group and 18 subjects (60%) in the clomiphene group, with a statistically significant difference between the two groups (p=0.024). Pregnancy occurred in 16 subjects (53.33%) in letrozole group and 7 subjects (23.33%) in clomiphene group, which shows statistically significant difference between the two groups (p=0.048).Conclusions: Though number of developing follicles was found statistically significant with clomiphene citrate but ovulation rate and pregnancy rate were higher with letrozole group. Therefore, letrozole is a safe and better alternative for ovulation induction in patients of anovulatory PCOS, and it may be considered as a first line treatment for ovulation induction in these patients.
- 27 May 2020
- Published by Medip Academy in International Journal of Reproduction, Contraception, Obstetrics and Gynecology
- Vol. 9 (6) , 2512-2515
Open AccessLomiphene citrate versus letrozole as first line ovulation induction drug in infertile anovulatory polycystic ovarian syndrome women: a prospective randomized controlled trial
Background: The present study was design to compare letrozole (5 mg) and clomiphene citrate (100 mg) as first line ovulation induction drug in infertile anovulatory polycystic ovarian syndrome (PCOS) women.Methods: This prospective randomized clinical trial included 60 cases of PCOS with anovulatory infertility. The first group comprised of 30 patients who received 5 mg letrozole daily and the second group received 100 mg clomiphene citrate daily for 5 days starting on day 2-5 of menses. Both the groups were followed by ultrasound for follicle monitoring, ovulation and endometrial thickness. When dominant follicle reaches a diameter of more than or equal to 18mm and endometrial thickness ≥7.5 mm, human chorionic gonadotrophin (hCG) 5,000 IU was given intramuscularly and timed intercourse was advised. Main outcome measures were occurrence of ovulation, endometrial thickness and pregnancy rates.Results: The mean age, body mass index, and number of cases of primary and secondary infertility in both the groups showed no statistically significant difference. Multi-follicular development during induction was statistically significantly greater in the clomiphene group (1.27±1.11 versus 2.03±1.65; p=0.041). Ovulation occurred in 24 subjects (80%) in letrozole group and 18 subjects (60%) in the clomiphene group, with a statistically significant difference between the two groups (p=0.024). Pregnancy occurred in 16 subjects (53.33%) in letrozole group and 7 subjects (23.33%) in clomiphene group, which shows statistically significant difference between the two groups (p=0.048).Conclusions: Though number of developing follicles was found statistically significant with clomiphene citrate but ovulation rate and pregnancy rate were higher with letrozole group. Therefore, letrozole is a safe and better alternative for ovulation induction in patients of anovulatory PCOS, and it may be considered as a first line treatment for ovulation induction in these patients.
- 4 May 2020
- Published by Georgetown University School of Medicine in Georgetown Medical Review
- Vol. 4 (1) , 12344
Stem Cell Therapies and Treatment Advances for Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is characterized by a left ventricular ejection fraction of 50% or greater. While heart failure with reduced ejection fraction (HFrEF) is well-characterized and has numerous treatment options, HFpEF remains poorly understood. HFpEF has long been termed diastolic dysfunction, because it was thought that fibrosis and impaired relaxation of the left ventricle could alone explain the underlying pathophysiology. However, recent research has identified additional mechanisms that influence HFpEF, specifically metabolic disorders and proinflammatory conditions. Despite this recent progress in elucidating the pathophysiology, there are still no approved treatment options that increase survival in patients with HFpEF. In the context of limited pharmacological options, stem cell therapy and cardiac biomarkers have emerged as potential breakthroughs in the treatment of HFpEF, but there has not yet been a review of their potential. This review evaluates the potential of cardiosphere-derived cells (CDCs), mesenchymal stromal cells (MSCs), and endothelial progenitor cells (EPCs) in the treatment of HFpEF. CDCs have shown promise, with a placebo-controlled animal trial demonstrating an increase in survival and a marked improvement in left ventricular end diastolic filling among the group treated with intracoronary infusion of CDCs. Additionally, with the newfound understanding of HFpEF pathophysiology, studies have also investigated the role MSCs and EPCs play in the inflammation associated with HFpEF, as well as the potential benefit these stem cells would bring to the treatment of HFpEF. While clinical trials are needed to confirm the safety and efficacy of these therapies, we offer insight into their potential, as well as a comprehensive summary of the pertinent clinical studies that are currently in progress. Embase, Ovid Medline, and PubMed were used to search all relevant literature for this review.
- 4 May 2020
- Published by Georgetown University School of Medicine in Georgetown Medical Review
- Vol. 4 (1) , 12344
Stem Cell Therapies and Treatment Advances for Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is characterized by a left ventricular ejection fraction of 50% or greater. While heart failure with reduced ejection fraction (HFrEF) is well-characterized and has numerous treatment options, HFpEF remains poorly understood. HFpEF has long been termed diastolic dysfunction, because it was thought that fibrosis and impaired relaxation of the left ventricle could alone explain the underlying pathophysiology. However, recent research has identified additional mechanisms that influence HFpEF, specifically metabolic disorders and proinflammatory conditions. Despite this recent progress in elucidating the pathophysiology, there are still no approved treatment options that increase survival in patients with HFpEF. In the context of limited pharmacological options, stem cell therapy and cardiac biomarkers have emerged as potential breakthroughs in the treatment of HFpEF, but there has not yet been a review of their potential. This review evaluates the potential of cardiosphere-derived cells (CDCs), mesenchymal stromal cells (MSCs), and endothelial progenitor cells (EPCs) in the treatment of HFpEF. CDCs have shown promise, with a placebo-controlled animal trial demonstrating an increase in survival and a marked improvement in left ventricular end diastolic filling among the group treated with intracoronary infusion of CDCs. Additionally, with the newfound understanding of HFpEF pathophysiology, studies have also investigated the role MSCs and EPCs play in the inflammation associated with HFpEF, as well as the potential benefit these stem cells would bring to the treatment of HFpEF. While clinical trials are needed to confirm the safety and efficacy of these therapies, we offer insight into their potential, as well as a comprehensive summary of the pertinent clinical studies that are currently in progress. Embase, Ovid Medline, and PubMed were used to search all relevant literature for this review.
- Open Access
- 10 January 2015
- Published by Sciencedomain International in Annual Research & Review in Biology
- Vol. 8 (6) , 1-8
AQP2 Genes and Nephrogenic Diabetes Insipidus: A Review
Nephrogenic Diabetes insipidus (NDI) is an issue coming about because of lacking against diuretic hormone (ADH) activity and is described by the entry of extensive measures of exceptionally dilute urine. This problem must be separated from other polyuric states, for example, essential polydipsia, osmotic diuresis and diabetes mellitus. Diabetes insipidus is a condition when a person is passing urine with excess of water, this condition arise due to improper re-absorption of water during urine formation. Aquaporins (AQPs) play a important role in absorption of water. AQP2 is quite dominant than other isoforms. This article provides nutshell information about Diabetes Insipidus and role of Aquaporin-2 gene in its physiology.
- 10 January 2015
- Published by Sciencedomain International in Annual Research & Review in Biology
- Vol. 8 (6) , 1-8
Open AccessAQP2 Genes and Nephrogenic Diabetes Insipidus: A Review
Nephrogenic Diabetes insipidus (NDI) is an issue coming about because of lacking against diuretic hormone (ADH) activity and is described by the entry of extensive measures of exceptionally dilute urine. This problem must be separated from other polyuric states, for example, essential polydipsia, osmotic diuresis and diabetes mellitus. Diabetes insipidus is a condition when a person is passing urine with excess of water, this condition arise due to improper re-absorption of water during urine formation. Aquaporins (AQPs) play a important role in absorption of water. AQP2 is quite dominant than other isoforms. This article provides nutshell information about Diabetes Insipidus and role of Aquaporin-2 gene in its physiology.